Advanced search
Publication Cover
Patient Preference and Adherence Volume 8, 2014 - Issue
Submit an article Journal homepage
317
Views
56
CrossRef citations to date
0
Altmetric
Review

Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis

Yoshito Takeda1 Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Osaka, JapanCorrespondence[email protected]
,
Kazuyuki Tsujino2 Department of Respiratory Medicine, Kinki Central Hospital of the Mutual Aid Association of Public School Teachers, Itami, Hyogo, Japan
,
Takashi Kijima1 Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
&
Atsushi Kumanogoh1 Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
Pages 361-370 | Published online: 21 Mar 2014

Citations (56)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Maria Hollmen, Marlies Wijsenbeek, Tom Bromilow, Adam B Smith, Stuart Mealing, Damian Lewis, Liam Galvin, Steve Jones, Guus Asijee, Stéphane Soulard & Antoine Froidure. (2023) I-PreFer Study: A Discrete Choice Experiment to Explore Patient, Caregiver and Pulmonologist Preferences of Idiopathic Pulmonary Fibrosis Pharmacological Treatment Options. Patient Preference and Adherence 17, pages 1895-1906.
Read now
Run Dong, Min Liu, Xiao-Xi Huang, Zheng Liu, Ding-Yuan Jiang, Hui-Juan Xiao, Jing Geng, Yan-Hong Ren & Hua-Ping Dai. (2020) Water-Soluble C60 Protects Against Bleomycin-Induced Pulmonary Fibrosis in Mice. International Journal of Nanomedicine 15, pages 2269-2276.
Read now
Jing Tang, Jianming Li, Guo Li, Haitao Zhang, Ling Wang, Dai Li & Jinsong Ding. (2017) Spermidine-mediated poly(lactic-co-glycolic acid) nanoparticles containing fluorofenidone for the treatment of idiopathic pulmonary fibrosis. International Journal of Nanomedicine 12, pages 6687-6704.
Read now
Galina Balakirski & Hans F. Merk. (2017) Cutaneous allergic drug reactions: update on pathophysiology, diagnostic procedures and differential diagnosic. Cutaneous and Ocular Toxicology 36:4, pages 307-316.
Read now

Articles from other publishers (52)

Zesergio Melo, Julio Palomino, Adriana Franco-Acevedo, David García, Ricardo González-González, Maritza G. Verdugo-Molinares, Eliseo Portilla-de Buen, Bibiana Moreno-Carranza, Clotilde Fuentes-Orozco, Francisco J. Barbosa-Camacho, Emilio A. Reyes-Elizalde, Laura Cortés-Sanabria & Alejandro González-Ojeda. (2023) Pharmacological Blockade of TGF-Beta Reduces Renal Interstitial Fibrosis in a Chronic Ischemia–Reperfusion Animal Model. Drugs and Drug Candidates 2:1, pages 137-147.
Crossref
Fateme Bahram Yazdroudi & Alaeddin Malek. (2022) Optimal control of TGF-β to prevent formation of pulmonary fibrosis. PLOS ONE 17:12, pages e0279449.
Crossref
Evgeny Bazdyrev, Maria Panova, Valeria Zherebtsova, Alexandra Burdenkova, Ivan Grishagin, Fedor Novikov & Vladimir Nebolsin. (2022) The Hidden Pandemic of COVID-19-Induced Organizing Pneumonia. Pharmaceuticals 15:12, pages 1574.
Crossref
Hayder M. Al-kuraishy, Gaber El-Saber Batiha, Hani Faidah, Ali I. Al-Gareeb, Hebatallah M. Saad & Jesus Simal-Gandara. (2022) Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals. Inflammopharmacology 30:6, pages 2017-2026.
Crossref
Anna Birnhuber, Katharina Jandl, Valentina Biasin, Elisabeth Fließer, Francesco Valzano, Leigh M. Marsh, Christina Krolczik, Andrea Olschewski, Jochen Wilhelm, Wolfgang Toller, Akos Heinemann, Horst Olschewski, Malgorzata Wygrecka & Grazyna Kwapiszewska. (2022) Pirfenidone exacerbates Th2-driven vasculopathy in a mouse model of systemic sclerosis-associated interstitial lung disease. European Respiratory Journal 60:4, pages 2102347.
Crossref
Javeria Anwar, Wing Tai Kong & Bathmapriya Balakrishnan. (2022) Updates in Hypersensitivity Pneumonitis: A Narrative Review. Current Pulmonology Reports 11:4, pages 106-115.
Crossref
Manas Sehgal, Sharayu Manish Jakhete, Amruta Ganesh Manekar & Satish Sasikumar. (2022) Specific epigenetic regulators serve as potential therapeutic targets in idiopathic pulmonary fibrosis. Heliyon 8:8, pages e09773.
Crossref
Martina Doubková. (2022) Antifibrotic therapy and its indications for interstitial pulmonary fibrosis. Vnitřní lékařství 68:4, pages 212-215.
Crossref
Vincent Cottin, Sonia Guéguen, Hilario Nunes, Stéphane Jouneau, Bruno Crestani, Philippe Bonniaud, Lidwine Wemeau, Dominique Israël-Biet, Martine Reynaud-Gaubert, Anne Gondouin, Jacques Cadranel, Sylvain Marchand-Adam, Marie Chevereau, Isabelle Dufaure-Garé, Serge Amselem, Annick Clément, Emmanuel Bergot, Philippe Bonniaud, Arnaud Bourdin, Jacques Cadranel, Cécile Chenivesse, Vincent Cottin, Bruno Crestani, Jean-Charles Dalphin, Claire Dromer, Emmanuel Gomez, Sandrine Hirschi, Dominique Israël-Biet, Stéphane Jouneau, Sylvain Marchand-Adam, David Montani, Hilario Nunes, Grégoire Prévot, Sébastien Quetant, Martine Reynaud-Gaubert, Dominique Valeyre & Lidwine Wemeau. (2021) Treatment of Idiopathic Pulmonary Fibrosis with Capsule or Tablet Formulations of Pirfenidone in the Real-Life French RaDiCo-ILD Cohort. Advances in Therapy 39:1, pages 405-420.
Crossref
Henrik Jessen, Nils Hoyer, Thomas S. Prior, Peder Frederiksen, Sarah R. Rønnow, Morten A. Karsdal, Diana J. Leeming, Elisabeth Bendstrup, Jannie M. B. Sand & Saher B. Shaker. (2021) Longitudinal serological assessment of type VI collagen turnover is related to progression in a real-world cohort of idiopathic pulmonary fibrosis. BMC Pulmonary Medicine 21:1.
Crossref
David R. CassattAlex Gorovets, Banu Karimi-Shah, Rosemary Roberts, Paul W. Price, Merriline M. SatyamitraNushin Todd, Sue-Jane Wang & Libero Marzella. (2021) A Trans-Agency Workshop on the Pathophysiology of Radiation-Induced Lung Injury. Radiation Research 197:4.
Crossref
Yoshiki Seto, Gen Suzuki, Asako Aoki, Yuuki Kaneko, Masashi Kato, Hideyuki Sato & Satomi Onoue. (2021) Novel approach for attenuation of pirfenidone-induced digestive symptoms: a respirable powder formulation of pirfenidone. Therapeutic Delivery 12:7, pages 515-522.
Crossref
Ge Zhang, He Chen, Yifan Guo, Wei Zhang, Qiuyu Jiang, Si Zhang, Liping Han, She Chen & Ruyi Xue. (2021) Activation of Platelet NLRP3 Inflammasome in Crohn’s Disease. Frontiers in Pharmacology 12.
Crossref
Lili Ding, Juan Yang, Chunmei Zhang, Xiuna Zhang & Pujun Gao. (2021) Neutrophils Modulate Fibrogenesis in Chronic Pulmonary Diseases. Frontiers in Medicine 8.
Crossref
Ji Zhang, Tao Wang, Ashmita Saigal, Josephine Johnson, Jennifer Morrisson, Sahba Tabrizifard, Scott A. Hollingsworth, Michael J. Eddins, Wenxian Mao, Kim O’Neill, Margarita Garcia-Calvo, Ester Carballo-Jane, DingGang Liu, Taewon Ham, Qiong Zhou, Weifeng Dong, Hsien-Wei Meng, Jacqueline Hicks, Tian-Quan Cai, Taro Akiyama, Shirly Pinto, Alan C. Cheng, Thomas Greshock, John C. Marquis, Zhao Ren, Saswata Talukdar, Hussam Hisham Shaheen & Masahisa Handa. (2021) Discovery of a new class of integrin antibodies for fibrosis. Scientific Reports 11:1.
Crossref
Shankar J. Evani, S. L. Rajasekhar Karna, Janakiram Seshu & Kai P. Leung. (2020) Pirfenidone regulates LPS mediated activation of neutrophils. Scientific Reports 10:1.
Crossref
Maha H. Sharawy & Marwa S. Serrya. (2020) Pirfenidone attenuates gentamicin-induced acute kidney injury by inhibiting inflammasome-dependent NLRP3 pathway in rats. Life Sciences 260, pages 118454.
Crossref
Daniel S. Glass, David Grossfeld, Heather A. Renna, Priya Agarwala, Peter Spiegler, Lora J. Kasselman, Amy D. Glass, Joshua DeLeon & Allison B. Reiss. (2020) Idiopathic pulmonary fibrosis: Molecular mechanisms and potential treatment approaches. Respiratory Investigation 58:5, pages 320-335.
Crossref
Hamidreza Aboulkheyr Es, Sareh Zhand, Jean Paul Thiery & Majid Ebrahimi Warkiani. (2020) Pirfenidone reduces immune-suppressive capacity of cancer-associated fibroblasts through targeting CCL17 and TNF-beta. Integrative Biology 12:7, pages 188-197.
Crossref
Anne-Ulrike Trendelenburg. 2020. Anti-fibrotic Drug Discovery. Anti-fibrotic Drug Discovery 1 36 .
Ixchel Lima-Posada, Francesco Fontana, Rosalba Pérez-Villalva, Nathan Berman-Parks & Norma A. Bobadilla. (2019) Pirfenidone prevents acute kidney injury in the rat. BMC Nephrology 20:1.
Crossref
Brandon Nokes, Eugene Golts & Kamyar Afshar. 2019. Interstitial Lung Diseases. Interstitial Lung Diseases.
C. Magnus Sköld, Lisen Arnheim-Dahlström, Karen Bartley, Christer Janson, Klaus-Uwe Kirchgaessler, Aaron Levine & Giovanni Ferrara. (2019) Patient journey and treatment patterns in adults with IPF based on health care data in Sweden from 2001 to 2015. Respiratory Medicine 155, pages 72-78.
Crossref
Amber Mortensen, Lauren Cherrier & Rajat Walia. (2018) Effect of pirfenidone on wound healing in lung transplant patients. Multidisciplinary Respiratory Medicine 13:1.
Crossref
Sally Ibbotson. (2020) Drug and chemical induced photosensitivity from a clinical perspective. Photochemical & Photobiological Sciences 17:12, pages 1885-1903.
Crossref
William M. Berkowski, Daniel J. Gibson, SooJung Seo, Laura R. Proietto, R. David Whitley, Gregory S. Schultz & Caryn E. Plummer. (2018) Assessment of Topical Therapies for Improving the Optical Clarity Following Stromal Wounding in a Novel Ex Vivo Canine Cornea Model. Investigative Opthalmology & Visual Science 59:13, pages 5509.
Crossref
Yuzhen Hu, Miao Li, Mengmeng Zhang & Yiguang Jin. (2018) Inhalation treatment of idiopathic pulmonary fibrosis with curcumin large porous microparticles. International Journal of Pharmaceutics 551:1-2, pages 212-222.
Crossref
Yanwu Sun, Yiyi Zhang & Pan Chi. (2018) Pirfenidone suppresses TGF‑β1‑induced human intestinal fibroblasts activities by regulating proliferation and apoptosis via the inhibition of the Smad and PI3K/AKT signaling pathway. Molecular Medicine Reports.
Crossref
Chang Li, Veronika Rezov, Emmi Joensuu, Ville Vartiainen, Mikko Rönty, Miao Yin, Marjukka Myllärniemi & Katri Koli. (2018) Pirfenidone decreases mesothelioma cell proliferation and migration via inhibition of ERK and AKT and regulates mesothelioma tumor microenvironment in vivo. Scientific Reports 8:1.
Crossref
Dan Lei, Yingxue Huang, Hongfu Xie, Yuxin Yi, Juan Long, Shangqing Lin, Chuchu Huang, Dan Jian & Ji Li. (2018) Fluorofenidone inhibits UV-A induced senescence in human dermal fibroblasts via the mammalian target of rapamycin-dependent SIRT1 pathway. The Journal of Dermatology 45:7, pages 791-798.
Crossref
Yan-Wu Sun, Yi-Yi Zhang, Xin-Jie Ke, Xue-jing Wu, Zhi-Fen Chen & Pan Chi. (2018) Pirfenidone prevents radiation-induced intestinal fibrosis in rats by inhibiting fibroblast proliferation and differentiation and suppressing the TGF-β1/Smad/CTGF signaling pathway. European Journal of Pharmacology 822, pages 199-206.
Crossref
Rokhsana Rasooli, Fatemeh Pourgholamhosein, Younes Kamali, Fatemeh Nabipour & Ali Mandegary. (2017) Combination Therapy with Pirfenidone plus Prednisolone Ameliorates Paraquat-Induced Pulmonary Fibrosis. Inflammation 41:1, pages 134-142.
Crossref
Rama Malaviya, Jeffrey D. Laskin & Debra L. Laskin. (2017) Anti-TNFα therapy in inflammatory lung diseases. Pharmacology & Therapeutics 180, pages 90-98.
Crossref
Xiao'an LiuYangfan YangXiujuan GuoLiling LiuKaili WuMinbin Yu. (2017) The Antiangiogenesis Effect of Pirfenidone in Wound Healing In Vitro . Journal of Ocular Pharmacology and Therapeutics 33:9, pages 693-703.
Crossref
B N M K Khanum, R Guha, V P Sur, S Nandi, S K Basak, A Konar & S Hazra. (2017) Pirfenidone inhibits post-traumatic proliferative vitreoretinopathy. Eye 31:9, pages 1317-1328.
Crossref
C. Robalo-Cordeiro, P. Campos, L. Carvalho, A. Borba, S. Clemente, S. Freitas, S. Furtado, J.M. Jesus, C. Leal, A. Marques, N. Melo, C. Souto-Moura, S. Neves, V. Sousa, A. Santos & A. Morais. (2017) Idiopathic pulmonary fibrosis in the era of antifibrotic therapy: Searching for new opportunities grounded in evidence. Revista Portuguesa de Pneumologia (English Edition) 23:5, pages 287-293.
Crossref
Gerhard Rogler & Martin Hausmann. (2017) Factors Promoting Development of Fibrosis in Crohn’s Disease. Frontiers in Medicine 4.
Crossref
Min-Young Park, Woo-Haing Shim, Jeong-Min Kim, Gun-Wook Kim, Hoon-Soo Kim, Hyun-Chang Ko, Moon-Bum Kim & Byung-Soo Kim. (2017) Pirfenidone-induced photo-allergic reaction in a patient with idiopathic pulmonary fibrosis. Photodermatology, Photoimmunology & Photomedicine 33:4, pages 209-212.
Crossref
Takuma Tsukioka, Shigekazu Takemura, Yukiko Minamiyama, Shinjiro Mizuguchi, Michihito Toda & Shigeru Okada. (2017) Attenuation of Bleomycin-Induced Pulmonary Fibrosis in Rats with S-Allyl Cysteine. Molecules 22:4, pages 543.
Crossref
Yani Liu, Jianhong Wu, Zhongfang Li, Ying Luo, Fandian Zeng & Shaojun Shi. (2016) Tolerability and Pharmacokinetics of Hydronidone, an Antifibrotic Agent for Hepatic Fibrosis, after Single and Multiple Doses in Healthy Subjects: an Open-Label, Randomized, Dose-Escalating, First-in-Human Study. European Journal of Drug Metabolism and Pharmacokinetics 42:1, pages 37-48.
Crossref
Raghu Kalluri. (2016) The biology and function of fibroblasts in cancer. Nature Reviews Cancer 16:9, pages 582-598.
Crossref
Christine A. Fiddler, Nicky Simler, Helen Parfrey, Ahmad Miremadi & Edwin R. Chilvers. (2016) Severe Colitis Associated with Pirfenidone Use in Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society 13:8, pages 1430-1432.
Crossref
Yoshiki Seto, Gen Suzuki, Sharon Shui Yee Leung, Hak-Kim Chan & Satomi Onoue. (2016) Development of an Improved Inhalable Powder Formulation of Pirfenidone by Spray-Drying: In Vitro Characterization and Pharmacokinetic Profiling. Pharmaceutical Research 33:6, pages 1447-1455.
Crossref
Yue-Han Wu, Xian-Wei Li, Wen-Qun Li, Xiao-Hui Li, Yuan-Jian Li, Gao-Yun Hu, Zhao-Qian Liu & Dai Li. (2016) Fluorofenidone attenuates bleomycin-induced pulmonary fibrosis by inhibiting eukaryotic translation initiation factor 3a (eIF3a) in rats. European Journal of Pharmacology 773, pages 42-50.
Crossref
Simona Zanotti, Cinzia Bragato, Andrea Zucchella, Lorenzo Maggi, Renato Mantegazza, Lucia Morandi & Marina Mora. (2016) Anti-fibrotic effect of pirfenidone in muscle derived-fibroblasts from Duchenne muscular dystrophy patients. Life Sciences 145, pages 127-136.
Crossref
Jae-Min Shin, Joo-Hoo Park, Il-Ho Park & Heung-Man Lee. (2015) Pirfenidone Inhibits Transforming Growth Factor β1-induced Extracellular Matrix Production in Nasal Polyp-derived Fibroblasts. American Journal of Rhinology & Allergy 29:6, pages 408-413.
Crossref
Yoshio Taguchi, Masahito Ebina, Seishu Hashimoto, Takashi Ogura, Arata Azuma, Hiroyuki Taniguchi, Yasuhiro Kondoh, Moritaka Suga, Hiroki Takahashi, Koichiro Nakata, Yukihiko Sugiyama, Shoji Kudoh & Toshihiro Nukiwa. (2015) Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan. Respiratory Investigation 53:6, pages 279-287.
Crossref
Wenrui Hao, Clay Marsh & Avner Friedman. (2015) A Mathematical Model of Idiopathic Pulmonary Fibrosis. PLOS ONE 10:9, pages e0135097.
Crossref
Christopher S. King & Steven D. Nathan. (2015) Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine 21:5, pages 479-489.
Crossref
Maha Abdalla, Harika Sabbineni, Roshini Prakash, Adviye Ergul, Susan C Fagan & Payaningal R Somanath. (2015) The Akt inhibitor, triciribine, ameliorates chronic hypoxia-induced vascular pruning and TGFβ-induced pulmonary fibrosis. British Journal of Pharmacology 172:16, pages 4173-4188.
Crossref
Wei Sun, Zhe-li Jiang, Lei Zhou, Rui-min Chen, Zhe Wang, Wan-shu Li, Shuo-min Jiang, Guo-xin Hu & Rui-jie Chen. (2015) Determination and pharmacokinetic study of pirfenidone in rat plasma by UPLC–MS/MS. Journal of Chromatography B 981-982, pages 14-18.
Crossref
Patricia L. Roche & Michael P. Czubryt. 2015. Cardiac Fibrosis and Heart Failure: Cause or Effect?. Cardiac Fibrosis and Heart Failure: Cause or Effect? 181 217 .

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.